Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.

@article{Abdelhamid2011ClinicalPF,
  title={Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.},
  author={Thoraya M Abdelhamid and Mohamed Samra and Hanan Mabrouk Ramadan and Marowa Mehessin and Nadia Mahmoud Mokhtar},
  journal={Journal of the Egyptian National Cancer Institute},
  year={2011},
  volume={23 1},
  pages={17-24}
}
BACKGROUND Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of NHL in Egypt. It represents about 49% of NHL presenting to the National Cancer Institute (NCI), Cairo University. CHOP regimen is the standard treatment used for NHL since the 1970s with only 30-40% overall survival. Recently, integration of Rituximab became a standard of care for patients with DLBCL. However, its widespread use in developing countries is still limited by the lack of financial coverage. Clinical… CONTINUE READING
6 Citations
20 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 20 references

Respect of average related dose intensity correlate with survival in diffuse large B-cell lymphoma patients treated by CHOP. National retrospective study (1995–2000)

  • A Bosly, D Bron, A Van Hoof, R De Bock, Z Berneman, A Ferrant
  • Poster presented at the 46th Annual meeting of…
  • 2004
1 Excerpt

Similar Papers

Loading similar papers…